Product
Alpha-1
Aliases
Alpha-1 MP, Prolastin-C
3 clinical trials
1 indication
Indication
Alpha-1 Antitrypsin DeficiencyClinical trial
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin DeficiencyStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin DeficiencyStatus: , Estimated PCD: 2028-09-01
Clinical trial
A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin DeficiencyStatus: Recruiting, Estimated PCD: 2025-03-14